Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

DiaMedica Therapeutics Inc. (DMAC) EBITDA Margin (2018)

DiaMedica Therapeutics (DMAC) has 1 years of EBITDA Margin data on record, last reported at 277.4% in Q3 2018.

  • For Q3 2018, EBITDA Margin changed N/A year-over-year to 277.4%; the TTM value through Jun 2019 reached 1811.8%, changed N/A, while the annual FY2024 figure was 71844.12%, 1588770.0% down from the prior year.
  • EBITDA Margin reached 277.4% in Q3 2018 per DMAC's latest filing.
  • Across five years, EBITDA Margin topped out at 277.4% in Q3 2018 and bottomed at 277.4% in Q3 2018.